---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002494"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:01:50.125773+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BCLI issues three convertible notes to institutional investors, total ~$329K principal

## Summary
- Vanquish Funding: $94.3K note (12% OID), convertible at 65% of lowest trading price upon default, matures Oct 2026.
- Quick Capital: $94.9K note (10% OID), convertible at 75% of lowest trading price upon default, matures Jan 2027.
- Auctus Fund: $140K note (12% OID), convertible at 65% of lowest trading price after 6 months or upon default, matures 12 months.
- Notes include default penalties of 150% of outstanding, cross-default provisions, and beneficial ownership limitations at 4.99%.
- Proceeds used for general working capital; issuance exempt under Section 4(a)(2) and Rule 506.

## SEC filing metadata
- accession: 0001104659-26-002494
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/0001104659-26-002494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/tm262523d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002494
- JSON: https://secwatch.observer/filing/0001104659-26-002494.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002494.txt

## Source-grounded claims
- claim_id: 52effbd0cd5e74f37e8bd6d7febe0eea10f4c091
  claim: BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. valued at aggregate principal amount of $94,300 (effective 2025-12-31).
  evidence_excerpt: On December 31, 2025, the Company entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., under which the Company issued a note in the aggregate principal amount of $94,300 (including $12,300 original issue discount) for aggregate purchase price proceeds of $82,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/0001104659-26-002494-index.htm
- claim_id: 9aee4b0749006f061bce21716500e97efb5ca8ba
  claim: BRAINSTORM CELL THERAPEUTICS INC. entered into Note Purchase Agreement with Quick Capital, LLC valued at principal amount of $94,875 (effective 2026-01-05).
  evidence_excerpt: On January 5, 2026, the Company entered into a Note Purchase Agreement with Quick Capital, LLC, under which the Company issued a convertible promissory note in the principal amount of $94,875
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/0001104659-26-002494-index.htm
- claim_id: c999d15db9176daadecdd20f025f1e4940d8d14c
  claim: BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Auctus Fund, LLC valued at aggregate principal amount of $140,000 (effective 2026-01-06).
  evidence_excerpt: On January 6, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC, under which the Company issued a convertible promissory note in the aggregate principal amount of $140,000, including a $14,000 original issue discount, for cash proceeds of $126,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/0001104659-26-002494-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.